See No Evil, Hear No Evil, Speak No Evil: Obesity
A CardioAdvocate Phenotype
See No Evil, Hear No Evil, Speak No Evil
Why Obesity Is the Disease Nobody Cares to Acknowledge
Case Presentation
Maria is a 48-year-old Latina woman presenting for routine follow-up. Her BMI is 38 kg/m², and her waist circumference is 42 inches (central obesity by any definition). Her hemoglobin A1c is 6.3%—not yet diabetic but clearly dysglycemic. Her lipid panel shows triglycerides 220 mg/dL and HDL cholesterol only 34 mg/dL. Her LDL cholesterol is 118 mg/dL, which her clinician called "acceptable." But her ApoB is 145 mg/dL—atherogenic particle burden is high. She's tried every diet she can find, lost weight temporarily, and gained it back. She's never been offered any anti-obesity medication. No one has discussed metabolic disease trajectory, glycemic control, or cardiovascular prevention in concrete terms. She feels like a failure.
Flying Under the Radar
Flying Under the Radar
Three monkeys, one tragedy.
In the classical imagery, the three wise monkeys symbolize "see no evil, hear no evil, speak no evil"—the practice of wilful blindness to wrongdoing. In the obesity epidemic, we're watching this play out in real time across three distinct populations: clinicians, insurers, and society itself.
See No Evil: Clinicians know obesity is a risk factor, but many don't diagnose it as a disease. The word itself—"obesity"—is often avoided in office notes. Weight loss is mentioned as lifestyle advice ("eat less, move more"), but never as the output of a failing organ system requiring pharmacotherapy. The metabolic dysfunction driving weight gain is invisible to them. The adiposopathy and insulin resistance that caused it are clinical mysteries.
Hear No Evil: Insurers systematically deny coverage for anti-obesity medications, often citing BMI thresholds that were written before robust efficacy data existed. According to recent analysis, 84% of commercially insured patients with obesity lack coverage for FDA-approved anti-obesity medications. When medications like semaglutide cost $1,300 monthly out-of-pocket, even motivated patients can't access them. In the words of Dr. Michael Albert, who studies anti-obesity medication access: the cost and coverage barrier have made effective treatment inaccessible to most people who need it.
Speak No Evil: Society stigmatizes obesity relentlessly. People are blamed for their weight, shamed in doctor's offices, and offered unproven supplements instead of medications proven in randomized trials. The cultural narrative remains: "You lack willpower; you need to try harder." Weight gain is reframed as a moral failing, not a medical problem. This shame silences patients and prevents them from seeking care.
The result: only approximately 2% of eligible obese patients in the United States are currently receiving anti-obesity medication—despite the evidence that these drugs reduce weight 15–22%, improve cardiometabolic risk markers, and may reduce cardiovascular events and mortality.
CardioAdvocate Checklist
For Patients with Obesity
For Clinicians Managing Patients with Obesity
Questions to Ask Your Clinician
Deep Dive: Understanding Obesity as Disease
It's Not "Calories In, Calories Out" — It's Biology
The reductionist formula "eat less, move more" has dominated obesity discourse for a century, and it has failed spectacularly. For decades, clinicians and patients alike have accepted the premise that obesity is a function of willpower and discipline. The science tells a different story.
Obesity has a strong genetic component. Twin and family studies demonstrate that 40–70% of obesity risk is heritable. But genes aren't destiny—they interact with environment (food availability, urban design, sleep disruption) and metabolic dysregulation (leptin resistance, disrupted hunger signaling, hypothalamic dysfunction).
Beyond genetics, epigenetics—the activation and silencing of genes without changing DNA sequence—plays a crucial role. Intrauterine malnutrition, maternal adiposopathy, gestational diabetes, and childhood trauma can all program the body toward insulin resistance and metabolic dysfunction. The developmental origins of health and disease (DOHaD) hypothesis is now mainstream in pediatric and metabolic medicine.
A window into obesity's biology—the "double burden" of malnutrition: In humanitarian aid settings, researchers have documented a striking paradox. Among Western Sahara refugees receiving food aid, obesity and metabolic disease emerged alongside undernutrition—the "double burden of malnutrition." Populations receiving calorie-dense but nutrient-poor food developed insulin resistance, dysfunctional adipose tissue, and cardiometabolic disease. This phenomenon, observed across developing nations during the "nutrition transition," illustrates a fundamental truth: obesity is not simply about eating too much. It is about what happens when metabolic machinery is exposed to the wrong inputs. The same biology plays out in American food deserts, where ultra-processed foods are the only affordable option. Science journalist Gary Taubes has drawn attention to the role of insulin and refined carbohydrates in fat storage, arguing that the conventional "calories in, calories out" model oversimplifies the hormonal drivers of adiposity. While his emphasis on insulin as a primary regulator has sparked important debate, the full picture is more nuanced: energy balance, hormonal signaling, gut microbiome, neurobiological appetite regulation, and environmental factors all interact. No single mechanism—whether insulin, calories, or carbohydrates—explains obesity alone. What the evidence does support is that the quality and composition of food matters as much as quantity, and that metabolic programming is far more complex than willpower.
This patient's story is representative of millions. The leptin-melanocortin pathway, orexigenic peptides (NPY, AgRP), anorexigenic peptides (POMC, CART), and the gut-brain axis all dysregulate in obesity. A comprehensive 2024 review in Endocrine Reviews details the appetite- and weight-regulating neuroendocrine circuitry that becomes dysregulated in obesity. It is not a choice. It is not laziness. It is neurobiology gone awry.
Adiposopathy — When Fat Gets Sick
Not all body fat is created equal. Adiposopathy—literally "sick fat"—describes dysfunctional adipose tissue characterized by inflammation, insulin resistance, and fibrosis.
Healthy adipose tissue is metabolically active, storing and releasing energy on demand, producing leptin and adiponectin (protective hormones), and maintaining a balance of anti-inflammatory immune cells. In obesity—especially visceral obesity—the adipose tissue becomes inflamed. Fat cells (adipocytes) enlarge through hypertrophy (cell size increase) or increase in number through hyperplasia. When fat cells grow too large, they outstrip their blood supply, leading to hypoxia (oxygen deprivation). Hypoxic adipocytes release inflammatory signals (TNF-α, IL-6) that recruit macrophages. These macrophages form "crown-like structures" around dying adipocytes—a histological hallmark of inflamed fat.
The National Lipid Association published a landmark consensus statement on adiposopathy in the Journal of Clinical Lipidology (2013), authored primarily by Dr. Harold Bays. The paper documents how inflamed adipose tissue becomes an endocrine organ pumping out inflammatory cytokines, free fatty acids, and dysfunctional adipokines. This drives insulin resistance, dyslipidemia, and cardiovascular disease. The adiposopathy phenotype—sick fat—is far more predictive of cardiometabolic risk than BMI alone.
The clinical implication: two patients with identical BMI can have vastly different metabolic phenotypes. One may have subcutaneous fat (less metabolically toxic), preserved insulin sensitivity, and low cardiovascular risk. The other may have visceral fat, severe insulin resistance, and be on the pathway to atherosclerotic disease. Cardiometabolic phenotyping matters more than weight number.
Visceral vs. Subcutaneous Obesity — The Geography of Fat
The location of fat matters. Visceral adipose tissue (belly fat, surrounding the organs) is metabolically more toxic than subcutaneous fat (under the skin). Visceral fat is more insulin-resistant, more inflammatory, and more lipolytic—it releases free fatty acids directly into the portal blood, driving liver dysfunction and dyslipidemia. Subcutaneous fat, while abundant, is relatively inert metabolically.
This geographic distinction helps explain part of the so-called "obesity paradox"—the observation that BMI alone is a poor discriminator of cardiovascular risk. A 2023 review in Frontiers in Cardiovascular Medicine confirmed that visceral adipose tissue is strongly associated with atherosclerosis, vulnerable plaque characteristics, and acute cardiovascular events, while subcutaneous fat shows opposing associations—the adjusted prevalence of aortic plaque actually decreases across tertiles of subcutaneous fat in obese adults. However, subcutaneous obesity is not entirely benign: overall excess adiposity—regardless of distribution—contributes to hypertension, heart failure, and left ventricular hypertrophy through volume expansion and hemodynamic effects. Importantly, the VAT/SAT ratio independently predicts cardiometabolic risk beyond BMI alone—Framingham Heart Study data show that the propensity to store fat viscerally versus subcutaneously is itself a unique risk factor, independent of absolute fat volumes.
The ethnic dimension is critical. Research on body composition across U.S. ethnic groups has shown that South Asian and Filipino populations accumulate significantly more visceral fat at lower BMI thresholds—the "thin-fat" phenotype. Filipino women had higher visceral adipose tissue volume than white or African-American women despite similar BMI and waist circumference. This explains why standard BMI cutoffs underestimate cardiovascular risk in these populations. The International Diabetes Federation consensus definition now recommends ethnic-specific waist circumference cutoffs for cardiovascular risk stratification: 94 cm for European men, 80 cm for European women, but lower thresholds for South Asian, Chinese, and Filipino populations due to their higher visceral fat burden at lower BMI.
The clinical message: ask about waist circumference, know the ethnic-specific cutoffs, and don't let BMI alone fool you into thinking a patient is low-risk. Fat distribution and metabolic phenotype trump statistics.
Insulin Resistance — The Metabolic Trap
At the heart of obesity—perhaps more accurately, at the heart of its cardiometabolic consequences—lies insulin resistance. This is not merely "bad glucose control." Insulin resistance represents a fundamental breakdown in how muscle, liver, and fat respond to the hormone that should be shuttling nutrients into cells.
In insulin resistance, the normal response to a meal is broken. Your liver still secretes insulin, often more of it, trying desperately to force glucose into resistant cells. The excess insulin drives fat storage—especially visceral fat storage—while simultaneously starving muscle and bone of glucose and amino acids. This creates a paradox: despite apparent caloric excess, the body is undernourished at the cellular level.
This paradox manifests in sarcopenic obesity—the loss of muscle mass despite high total body weight. A 300-pound woman may have only 80 pounds of muscle mass (normal for her height would be 120 pounds). Her muscles are starving for glucose while her fat cells are drowning in it. The result: weakness, falls, reduced metabolic rate (muscle burns calories even at rest), and worsened metabolic dysfunction.
Similarly, insulin resistance and obesity lead to osteopenic obesity—loss of bone mineral density despite excess body weight. Traditionally, clinicians thought overweight patients had protective excess weight for bone. It's the opposite: hyperinsulinemia and inflammatory cytokines impair osteoblast function, while the lack of mechanical load (since fat provides weight but poor-quality movement) and vitamin D deficiency all combine to weaken bone. Obese patients fracture more easily than lean ones, not less. This is a second paradox: weight-dependent protection without the protection.
These twin presentations—sarcopenia and osteopenia, both in the setting of obesity—mirror patterns seen in classical starvation and malnutrition. The biochemistry has recognized this: a severely obese, insulin-resistant patient may have circulating amino acid patterns similar to someone who is genuinely malnourished. The cells cannot access the nutrients despite systemic abundance.
Insulin resistance also drives atherogenic dyslipidemia. High insulin and insulin resistance force the liver to overproduce VLDL particles, leading to elevated triglycerides and low HDL cholesterol. The LDL particles that result are small and dense—far more atherogenic than large, buoyant LDL. The apolipoprotein B burden (the true count of atherogenic particles) skyrockets. This triad—high triglycerides, low HDL, small dense LDL—is called atherogenic dyslipidemia, and it is the lipid fingerprint of insulin resistance.
HOMA-IR (Homeostasis Model Assessment for Insulin Resistance) and fasting insulin are screening tools clinicians can use to quantify insulin resistance. A fasting insulin >12 mIU/L suggests significant insulin resistance and should prompt metabolic investigation and intervention. A HOMA-IR >2.5 is generally considered abnormal and predicts future diabetes. For patients with obesity, these values often far exceed normal—fasting insulin levels of 20–30 mIU/L are common, indicating profound metabolic dysfunction.
This foundation—insulin resistance driving both weight gain and atherogenic dyslipidemia—explains why obese patients are at extreme cardiovascular risk even before they develop diabetes. The lipid dysregulation is already underway. The 2024 guidelines from the Obesity Management Association and National Lipid Association emphasize that insulin resistance and obesity are root causes of atherosclerotic dyslipidemia. CardioAdvocate has published extensively on the Atherogenic Triad—this intersection is where the three monkeys have done their greatest damage.
The Atherogenic Lipid Profile of Obesity
The cholesterol panel that most clinicians review is incomplete for assessing atherosclerotic risk in obesity. Most practices report three values: LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), and triglycerides. These three alone miss critical information about particle burden and size distribution.
In obesity—especially with insulin resistance—the lipid pattern follows a predictable pattern:
- Elevated triglycerides (often 200–400 mg/dL)
- Low HDL cholesterol (often <35 mg/dL)
- Small dense LDL particles (detected by NMR lipoprofile or advanced panels)
- High ApoB (often 140–180 mg/dL or higher)
- Elevated remnant cholesterol (cholesterol in triglyceride-rich remnant particles)
This constellation is far more atherogenic than the same LDL-C level would suggest in a non-insulin-resistant patient. A patient with obesity, triglycerides 250 mg/dL, HDL 32 mg/dL, and LDL-C 130 mg/dL might appear "borderline" by traditional standards. But her ApoB is 165 mg/dL—extremely high. She has hundreds of small, dense LDL particles compared to a metabolically healthy person with LDL-C 130 mg/dL.
Why does LDL-C alone miss the risk? Because LDL-C measures the weight of cholesterol in LDL particles, not the number of particles. Imagine counting the weight of vehicles on a highway (LDL-C) versus counting the number of vehicles (LDL particle count, which ApoB represents). Ten large trucks might weigh 500 tons; 500 motorcycles might weigh only 100 tons. Would you conclude the motorcycles pose greater traffic risk? Of course not—but if you only had weight, you'd miss the hazard. Similarly, a patient with fewer, larger LDL particles (lower particle count) may have the same or higher LDL-C as someone with many small particles. The small-particle patient is at greater risk for atherosclerosis, but standard lipid panels don't distinguish this.
The SURMOUNT-5 trial, published in NEJM, compared tirzepatide head-to-head against semaglutide in patients with obesity and demonstrated superior lipid improvements with tirzepatide—particularly reductions in triglycerides and remnant cholesterol. Both agents improve the atherogenic dyslipidemia phenotype, but the magnitude of triglyceride reduction matters for patients with metabolic syndrome.
The European Society of Cardiology and European Atherosclerosis Society issued Class Ia recommendations (highest level of evidence, universal benefit) for ApoB measurement in patients with metabolic syndrome and obesity. ApoB is now preferred over LDL-C for guiding therapy intensity in these patients. Yet fewer than 20% of obese patients in routine practice have ApoB measured.
CardioAdvocate has written extensively on lipid assessment in the What's Your ApoB? and Atherogenic Triad articles, which cover lipid assessment in detail. The intersection with obesity adds urgency: obese patients need aggressive lipid management because their baseline burden of atherogenic particles is high, and time may already be slipping away.
Obesity and Procedural Risk — The Compounding Effect
For patients with obesity who require cardiac procedures—coronary intervention (PCI), cardiac surgery, or even catheter ablation for atrial fibrillation—obesity is a risk amplifier. Complication rates rise across the board: surgical wound infections, venous thromboembolism (VTE), bleeding, and prolonged intensive care stays all increase.
The mechanisms are multiple: mechanical difficulty with vascular access, reduced mobility and lymphatic drainage post-operatively, altered drug metabolism, difficult airway management, and impaired immune function in the setting of adiposopathy. The National Surgical Quality Improvement Program (NSQIP) database has documented that obese patients undergoing cardiac surgery have higher mortality, morbidity, and resource utilization.
The arrhythmia story is particularly striking. Atrial fibrillation (AF) is driven by obesity through multiple mechanisms: epicardial adipose tissue (cardiac fat pad) that inflames the atrial myocardium, diastolic dysfunction from obesity-related cardiomyopathy, and activation of the renin-angiotensin-aldosterone system. The epidemiologic data are clear: for every 5 kg/m² increase in BMI, AF recurrence risk increases approximately 15% after ablation.
But here's the redemptive part: weight loss works. The landmark LEGACY Study (Pathak et al., JACC 2015, PMID: 25792361) enrolled patients with paroxysmal AF and randomized them to weight loss intervention versus usual care. Patients who achieved ≥10% weight loss had a 6-fold greater probability of arrhythmia-free survival compared to those who did not lose weight. Not modest improvement—six-fold. This is one of the most impressive primary prevention outcomes in cardiology literature.
AF is a leading cause of stroke, and stroke is the leading cause of permanent disability in the United States. Prevention of AF through weight loss has cascading benefits for quality of life and independence.
The mechanism linking obesity to AF is increasingly understood. Epicardial adipose tissue—the visceral fat pad directly surrounding the heart—acts as a paracrine organ, releasing inflammatory mediators (IL-6, TNF-α, leptin) that permeate the atrial wall, driving remodeling and arrhythmogenesis. Newer anti-obesity medications show promise for reducing epicardial fat: GLP-1 receptor agonists have been shown to reduce epicardial adipose tissue thickness by approximately 20% in clinical studies. SGLT2 inhibitors similarly show benefit for cardiac remodeling and may reduce epicardial fat.
For the obese patient with AF, the pathway is clear: medication plus weight loss targeting procedural optimization and arrhythmia prevention is not optional—it's evidence-based standard of care.
A Brief History of How We Got Here
Understanding the obesity epidemic requires understanding its context. The modern obesity crisis did not emerge from individual moral failure; it emerged from structural, environmental, and policy changes that occurred over a single human lifetime.
In the 1950s–60s, the mass production and marketing of ultra-processed foods accelerated. Fast food chains proliferated. Home cooking, which had been the norm, began declining. Portion sizes expanded. Simultaneously, urban sprawl reduced walkable communities, and television became a dominant leisure activity.
A watershed moment arrived in 1977 with the McGovern Committee, which issued the first U.S. dietary guidelines, recommending the public reduce fat intake and increase carbohydrate consumption. The science supporting this recommendation was weak, and the food industry lobbied aggressively against fat-restriction language. Nevertheless, the guideline stood, and the low-fat craze of the 1980s–90s followed.
Here is the tragic irony: fat was removed from processed foods. But fat carries flavor and satiety. When removed, food manufacturers compensated by adding sugar and refined carbohydrates—particularly high-fructose corn syrup, which is cheaper and sweeter than sucrose. The "fat-free" cookie boom filled grocery stores. People ate more, thinking they were eating healthily. Obesity and diabetes rose in parallel.
Food industry lobbying has also shaped policy subtly. The original food pyramid recommended 6–11 servings of grains daily—far more than modern guidelines support. This was driven partly by agricultural subsidies favoring wheat and corn, not by nutritional science. The result: a generation consuming excessive refined carbohydrates.
Socioeconomic factors compound the picture. In urban and rural food deserts—areas with minimal access to fresh produce—ultra-processed, calorie-dense foods are the only readily available option. A single parent working two jobs cannot easily prepare home-cooked meals. They feed their children what is affordable and convenient. The child's metabolic programming is altered by this environment. Years later, that child struggles with obesity despite being told they lack willpower.
The point is not to assign blame but to acknowledge: individual behavior occurs within structural constraints. A person living in a food desert with limited income cannot simply "eat less, move more." The environment is working against them. Fixing obesity at population scale requires environmental and policy changes—not just individual exhortation.
Treatment: We Are in an Incredible Era
Diet — The Hardest Conversation
Diet is where the obesity conversation often derails. Diet studies are notoriously difficult to conduct because adherence is poor. Patients are asked to count calories, restrict macronutrients, or follow rigid meal plans. Most people, when left to their own devices, abandon structured diets within weeks. The oft-cited statistic: 95% of weight loss from diet alone is regained within 1–5 years.
What does work? The most successful diet is the one a person can adhere to long-term. This might be low-carbohydrate, low-fat, Mediterranean, DASH, or something else entirely. There is no "best" diet in absolute terms—there is only the best diet for that individual.
A landmark randomized trial published in JAMA (Dansinger et al., 2005) compared the Atkins, Zone, Ornish, and Weight Watchers diets head-to-head in 160 participants. The result? No significant difference in weight loss between diets at one year. What predicted success was not which diet a patient chose but whether they stuck with it. Adherence rates were low across all groups, and those who adhered lost weight regardless of macronutrient composition. The lesson was clear: the best diet is the one a person can follow long-term.
The National Lipid Association's 2023 nutrition guidelines, co-authored by Carol Kirkpatrick, PhD, RDN, emphasize individualized, patient-centered dietary counseling over rigid prescriptions. Rather than imposing a single dietary pattern, the NLA recommends working with patients to identify their barriers, preferences, and sustainable changes. A physician who says "You need to follow the ketogenic diet" or "You must go vegan" without understanding the patient's life context will fail. A physician who says "What eating pattern have you been able to sustain in the past? Let's build on that" is more likely to succeed.
The broader point: diet tribalism—the notion that one diet is objectively superior to all others—is unhelpful and unsupported by evidence. Patients should be empowered to find the dietary approach that works for their body, their preferences, and their life, with professional guidance.
Pharmacotherapy — The GLP-1 Revolution
The landscape of anti-obesity medication has transformed in the past five years. What was once a backwater of medicine is now at the forefront of cardiovascular and metabolic prevention.
Semaglutide (Wegovy) was the first to demonstrate cardiovascular benefit in a large outcomes trial. The SELECT trial (published in NEJM) enrolled approximately 17,600 people with obesity (BMI ≥30) or overweight with cardiometabolic comorbidity (BMI ≥27) who had established cardiovascular disease or cardiovascular risk factors. Half received semaglutide 2.4 mg weekly (Wegovy); half received placebo. The semaglutide group achieved approximately 10–15% weight loss. More importantly, they experienced a 20% relative reduction in major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, or cardiovascular death). This was landmark. For the first time, an obesity medication reduced hard cardiovascular endpoints.
Tirzepatide (Zepbound, Mounjaro), a GLP-1/GIP receptor agonist, has demonstrated even more impressive weight loss in the SURMOUNT trials. In SURMOUNT-2, patients achieved approximately 20% weight loss at 72 weeks with the highest dose (22.5 mg weekly). In SURMOUNT-5 (published in NEJM), tirzepatide was compared head-to-head against semaglutide in patients with obesity and type 2 diabetes. Tirzepatide achieved greater weight loss (21% vs. 16%) and superior reduction in A1c. Whether tirzepatide will demonstrate cardiovascular benefit equivalent to or exceeding semaglutide remains to be seen (cardiovascular outcome trials are ongoing), but the early metabolic signals are encouraging.
The barrier to these medications is not efficacy—it is cost and access. Dr. Michael Albert, MD, who researches anti-obesity medication access, has documented that semaglutide costs $1,300–$1,500 monthly without insurance coverage. For a low-income patient, this is insurmountable. Even with insurance, prior authorizations and formulary restrictions delay access. Dr. Spencer Nadolsky, DO, and his brother Dr. Karl Nadolsky, DO—both board-certified in obesity medicine—have been vocal advocates for addressing these barriers, fighting for policy changes to expand coverage and documenting the real-world impact of insurance denials on patients who need treatment.
As mentioned earlier, only approximately 2% of eligible obese patients in the United States are currently receiving anti-obesity medication. The crisis is not lack of efficacy; it is lack of access driven by cost and insurance denial.
Beyond GLP-1 RAs, SGLT2 inhibitors play a complementary role. These agents lower blood glucose by promoting urinary glucose excretion, and they have cardiovascular and kidney benefits independent of weight loss. In some patients, combining a GLP-1 RA with an SGLT2 inhibitor yields additive metabolic benefits.
In the near future, oral formulations of semaglutide and tirzepatide are expected to enter the market, potentially reducing cost and improving adherence compared to weekly injections. The landscape is evolving rapidly.
Bariatric Surgery — Proven Long-Term Results
Bariatric surgery—gastric bypass, sleeve gastrectomy, biliopancreatic diversion—has proven long-term benefits that span decades. For far too long, surgery was presented as a "last resort" for the morbidly obese, as if it were a failure of willpower. The data contradict this framing. Surgery is a proven treatment for a chronic disease, no different in principle from coronary artery bypass graft for coronary artery disease.
The Swedish Obese Subjects (SOS) Study (Sjöström et al., NEJM 2020), a 20-year observational cohort, followed over 4,000 obese patients (approximately 2,000 underwent bariatric surgery; 2,000 received usual care). The surgical group experienced 25% mortality reduction, significantly lower incidence of type 2 diabetes, myocardial infarction, and stroke, and even a reduction in cancer incidence. These benefits persisted 10–20 years post-operatively. This is not a cosmetic outcome; this is life-saving medicine.
The STAMPEDE trial (Schauer et al., NEJM 2017) compared bariatric surgery (gastric bypass or sleeve gastrectomy) plus intensive medical therapy versus intensive medical therapy alone in patients with type 2 diabetes and obesity. At 5 years, the surgical group had a 29% rate of A1c ≤6.0% (glycemic remission) versus only 5% in the medical group. Far more patients achieved diabetes remission with surgery. Surgery was superior for achieving metabolic targets and reducing medication burden. The ARMMS collaborative—combining STAMPEDE with other randomized bariatric trials—continues to report durable metabolic benefits beyond a decade of follow-up.
For the obese patient with poorly controlled diabetes despite medications, bariatric surgery is not a last resort—it is an option with superior long-term outcomes compared to medical management alone. The same applies to patients with obesity and AF: weight loss (via diet, medication, or surgery, or combination) has the highest-quality evidence for AF prevention.
The Insurance Barrier — The Final Insult
In 2013, the American Medical Association officially recognized obesity as a disease—a significant symbolic and practical victory. A disease diagnosis opens doors for research funding, insurance coverage, and medical legitimacy.
Yet a decade later, coverage remains abysmal. According to recent data, 84% of commercially insured patients lack medication coverage for FDA-approved anti-obesity medications, and 76% lack coverage for bariatric surgery. Most require a BMI ≥35 (or ≥30 with comorbidity) for surgery approval, and many deny tirzepatide while covering only semaglutide—or vice versa. Some plans require documented failure of multiple diets before approving medication. The prior authorization process can take weeks, during which a motivated patient loses momentum.
A 2023 analysis in Frontiers in Public Health examined whether the AMA's 2013 disease classification led to improved medication coverage. The findings: no significant change in coverage policies post-classification. Formal recognition as a disease did not translate to expanded access. The system, it seems, does not care.
The cruelty is profound: proven treatments exist. A person with obesity and atrial fibrillation now has a medication (semaglutide or tirzepatide) that reduces AF recurrence. A person with obesity and type 2 diabetes can achieve remission with surgery. Yet their insurance company—often a for-profit entity that has never met them—denies access based on actuarial calculations.
Change requires advocacy. Patients must demand coverage. Physicians must document medical necessity clearly and appeal denials. Employer groups and legislative bodies must pressure insurers to align policy with evidence. CardioAdvocate believes in speaking up—demanding that the system do better. You deserve access to treatment, not shame.
The Bottom Line
The Bottom Line
Obesity is a chronic, relapsing, neuroendocrine disease driven by genetics, environment, and metabolic programming. It is not a lifestyle choice. It is not a character flaw. It is a failure of systems—your body's regulatory systems and the health care and insurance systems designed to help you.
You are not failing. The system is.
We have medications reducing major cardiovascular events by 20%. We have surgeries with decades of outcome data showing mortality reduction, diabetes remission, and AF prevention. We have understanding of the biology—adiposopathy, insulin resistance, leptin resistance, epicardial inflammation—that explains why willpower alone fails.
The three monkeys—see no evil, hear no evil, speak no evil—are the barriers. Clinicians who don't diagnose obesity as disease. Insurers who deny evidence-based treatment. A society that blames instead of helping. These are the real problem.
You deserve treatment. You deserve access. You deserve respect.
CardioAdvocate helps people understand what matters — and how to speak up about it.
